A cross-sectional survey of current treatment and symptom burden of patients with COPD consulting for routine care according to GOLD 2014 classifications

References

• MiravitllesMWorthHSoler CatalunaJJObservational study to characterise 24-hour COPD symptoms and their relationship with patient-reported outcomes: results from the ASSESS studyRespir Res20141512225331383
   PubMed Web of Science ®Google Scholar
• Global Initiative for Chronic Obstructive Lung DiseaseGlobal Strategy for the Diagnosis, Management and Prevention of COPDGlobal Initiative for Chronic Obstructive Lung Diseases (GOLD)2017 [updated 2017]. Available from: http://www.goldcopd.orgAccessed November 18, 2016
   Google Scholar
• KesslerRPartridgeMRMiravitllesMSymptom variability in patients with severe COPD: a pan-European cross-sectional studyEur Respir J201137226427221115606
   PubMed Web of Science ®Google Scholar
• PriceDSmallMMilliganGHigginsVGilEGEstruchJImpact of night-time symptoms in COPD: a real-world study in five European countriesInt J Chron Obstruct Pulmon Dis2013859560324348032
   PubMed Web of Science ®Google Scholar
• MullerovaHLuCLiHTabbererMPrevalence and burden of breathlessness in patients with chronic obstructive pulmonary disease managed in primary carePLoS One201491e8554024427316
   PubMed Web of Science ®Google Scholar
• AhmedTStewardJAO’MahonyMSDyspnoea and mortality in older people in the community: a 10-year follow-upAge Ageing201241454554922522776
   PubMed Web of Science ®Google Scholar
• LangePMarottJLVestboJNordestgaardBGPrevalence of nighttime dyspnoea in COPD and its implications for prognosisEur Respir J20144361590159824488571
   PubMed Web of Science ®Google Scholar
• RocheNSmallMBroomfieldSHigginsVPollardRReal world COPD: association of morning symptoms with clinical and patient reported outcomesCOPD201310667968624127914
   PubMedGoogle Scholar
• Global Initiative for Chronic Obstructive Lung DiseaseGlobal Strategy for the Diagnosis, Management and Prevention of COPDGlobal Initiative for Chronic Obstructive Lung Diseases (GOLD)2016 [updated 2016]. Available from: http://www.goldcopd.orgAccessed October 30, 2016
   Google Scholar
• Global Initiative for Chronic Obstructive Lung DiseaseGlobal Strategy for the Diagnosis, Management and Prevention of COPDGlobal Initiative for Chronic Obstructive Lung Diseases (GOLD)2014 [updated Jan 1, 2014. Available from: http://www.goldcopd.orgAccessed October 30, 2016
   Google Scholar
• JonesPMiravitllesMvan derMTKulichKBeyond FEV(1) in COPD: a review of patient-reported outcomes and their measurementInt J Chron Obstruct Pulmon Dis2012769770923093901
   PubMed Web of Science ®Google Scholar
• FranssenFMSpruitMAWoutersEFDeterminants of polypharmacy and compliance with GOLD guidelines in patients with chronic obstructive pulmonary diseaseInt J Chron Obstruct Pulmon Dis2011649350122069360
   PubMed Web of Science ®Google Scholar
• PriceDWestDBrusselleGManagement of COPD in the UK primary-care setting: an analysis of real-life prescribing patternsInt J Chron Obstruct Pulmon Dis2014988990425210450
   PubMed Web of Science ®Google Scholar
• KoblizekVPecenLZatloukalJReal-life GOLD 2011 implementation: the management of COPD lacks correct classification and adequate treatmentPLoS One2014911e11107825380287
   PubMed Web of Science ®Google Scholar
• VestboJVogelmeierCSmallMHigginsVUnderstanding the GOLD 2011 Strategy as applied to a real-world COPD populationRespir Med2014108572973624675239
   PubMed Web of Science ®Google Scholar
• WhitePThorntonHPinnockHGeorgopoulouSBoothHPOver-treatment of COPD with inhaled corticosteroids–implications for safety and costs: cross-sectional observational studyPLoS One2013810e7522124194824
   PubMed Web of Science ®Google Scholar
• AndersonPBenfordMHarrisNKaravaliMPiercyJReal-world physician and patient behaviour across countries: disease-specific programmes–a means to understandCurr Med Res Opin200824113063307218826746
   PubMed Web of Science ®Google Scholar
• JonesPWHardingGBerryPWiklundIChenWHKline LeidyNDevelopment and first validation of the COPD assessment testEur Respir J200934364865419720809
   PubMed Web of Science ®Google Scholar
• PriceDMiravitllesMPavordIFirst maintenance therapy for COPD in the UK between 2009 and 2012: a retrospective database analysisNPJ Prim Care Respir Med2016261606127808096
   PubMed Web of Science ®Google Scholar
• BrusselleGPriceDGruffydd-JonesKThe inevitable drift to triple therapy in COPD: an analysis of prescribing pathways in the UKInt J Chron Obstruct Pulmon Dis2015102207221726527869
   PubMed Web of Science ®Google Scholar
• SeamanJLeonardACPanosRJHealth care utilization history, GOLD guidelines, and respiratory medication prescriptions in patients with COPDInt J Chron Obstruct Pulmon Dis20105899720463890
   PubMedGoogle Scholar
• CorradoARossiAHow far is real life from COPD therapy guidelines? An Italian observational studyRespir Med2012106798999722483189
   PubMed Web of Science ®Google Scholar
• AppletonSPoolePSmithBVealeALassersonTJChanMMLong-acting beta2-agonists for poorly reversible chronic obstructive pulmonary diseaseCochrane Database Syst Rev20063CD001104
   Google Scholar
• BarrRGBourbeauJCamargoCARamFSInhaled tiotropium for stable chronic obstructive pulmonary diseaseCochrane Database Syst Rev20052CD002876
   Google Scholar
• DonohueJFSinghDMunzuCKilbrideSChurchAMagnitude of umeclidinium/vilanterol lung function effect depends on monotherapy responses: results from two randomised controlled trialsRespir Med2016112657426797016
   PubMed Web of Science ®Google Scholar
• NanniniLJLassersonTJPoolePCombined corticosteroid and long-acting beta(2)-agonist in one inhaler versus long-acting beta(2)-agonists for chronic obstructive pulmonary diseaseCochrane Database Syst Rev20129CD006829
   PubMed Web of Science ®Google Scholar
• MagnussenHDisseBRodriguez-RoisinRWithdrawal of inhaled glucocorticoids and exacerbations of COPDN Engl J Med2014371141285129425196117
   PubMed Web of Science ®Google Scholar
• NadeemNJTaylorSJEldridgeSMWithdrawal of inhaled corticosteroids in individuals with COPD–a systematic review and comment on trial methodologyRespir Res20111210721838890
   PubMed Web of Science ®Google Scholar
• WeiYFKuoPHTsaiYHFactors associated with the prescription of inhaled corticosteroids in GOLD group A and B patients with CInt J Chron Obstruct Pulmon Dis2015101951195626392770
   PubMed Web of Science ®Google Scholar
• DrivenesEOstremAMelbyeHPredictors of ICS/LABA prescribing in COPD patients: a study from general practiceBMC Fam Pract2014154224597538
   PubMed Web of Science ®Google Scholar
• WedzichaJABanerjiDChapmanKRIndacaterol-glycopyrronium versus salmeterol-fluticasone for COPDN Engl J Med2016374232222223427181606
   PubMed Web of Science ®Google Scholar
• HoritaNGotoAShibataYLong-acting muscarinic antagonist (LAMA) plus long-acting beta-agonist (LABA) versus LABA plus inhaled corticosteroid (ICS) for stable chronic obstructive pulmonary disease (COPD)Cochrane Database Syst Rev20172CD01206628185242
   PubMed Web of Science ®Google Scholar